The field of oncology has always been a "field of war" for pharmaceutical companies. According to public data, the global oncology drug market will exceed 150 billion U.S. dollars in 2020, and the top ten oncology drugs on the best-selling list will sell for more than 70 billion U.S. dollars in total, accounting for nearly half of the market...

Which varieties can successfully make the list? Without further ado, it will be announced immediately!

At the top of the list is Merck’s Pembrolizumab (commonly known as Drug K), with global sales of US$14.38 billion in 2020, a year-on-year increase of 30%. Since entering China in September 2018, Kerida’s sales have achieved breakthrough growth; in 2019, it broke through the 10 billion U.S. dollar mark with a growth rate of 54.1%, bringing Merck’s sales revenue of 11.048 billion U.S. dollars, climbing to Second place on the global drug bestseller list.

With its advantages in first-line non-small cell lung cancer and the expansion of other tumor indications, Kerida's sales in 2021 are expected to reach 16.8 billion U.S. dollars. According to EvaluatePharma's prediction, by 2024, K drug will replace Humira and become the next-generation "drug king" of the world's best-selling drugs, with revenues exceeding US$20 billion.

Bristol-Myers Squibb's lenalidomide is also strong, winning $12.106 billion in 2020, an impressive year-on-year increase of 10.60%. As an anti-tumor blockbuster in the immunomodulator category, Ruifumei ranked first in the top 10 best-selling anti-tumor drugs with sales of 9.685 billion U.S. dollars in 2018; in 2019, it ranked third in the world's top 10 best-selling drugs with sales of 10.823 billion U.S. dollars. In recent years, the global sales of this product have maintained double-digit growth, and the market potential is huge.

At the same time, five domestic companies including Hausen, Qilu, Yangtze River, Chia Tai Tianqing and Beijing Shuanglu have been approved to produce lenalidomide capsules, and they have all passed the consistency evaluation. In the face of competing products of similar types, fierce drug price wars will be triggered at any time.

In addition, Bristol-Myers Squibb's nivolumab (commonly known as O drug) also entered the top four, and in 2020, it won a sales of 6.992 billion US dollars. As the world's first PD-1/PD-L1 inhibitor, by virtue of its first launch advantage, O drug took the lead in occupying the cancer market, further consolidating the leading position of BMS in the global oncology business.

Ibrutinib's research and development companies-Johnson & Johnson and AbbVie, have achieved great success in the market since the two merged. Global sales have increased from US$692 million in 2014 to US$9.442 billion in 2020, becoming the fastest-growing anti-tumor drug in sales and the top selling of tinib drugs in one fell swoop.

The world's first marketed BTK inhibitor-ibrutinib, has been approved for 6 indications: chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, transplantation Anti-host disease and marginal zone lymphoma, and another 10 indications are under development.

Pfizer’s piperacillil is the world’s first CDK4/6 inhibitor to be marketed, ranking No. 5 with sales of US$5.392 billion, an increase of 8.7% over 2019. Since it was approved in 2015, Aiboxin’s sales revenue has been envious of others, and has grown rapidly over the years; it exceeded 2 billion in 2016, exceeded 3 billion in 2017, exceeded 4 billion in 2018, and $4.961 billion in 2019, a year-on-year increase of 20%. The future market expectation of piperacillil is very positive, and the breast cancer market position has undoubtedly surpassed Roche's trastuzumab.

Bevacizumab and Trastuzumab, which are two of Roche’s "troika", suffered a rapid decline in sales revenue last year due to the impact of biosimilar drugs. However, they rely on their excellent reputation for curative effects and a wide range of indications for tumor expansion. , Can not stop it from becoming a major tumor drug in the mainstream. Avastin and Herceptin will receive 5.321 billion U.S. dollars and 3.978 billion U.S. dollars in sales in the global market in 2020, ranking sixth and tenth on the list.

In addition, AstraZeneca’s oscitinib, Johnson & Johnson’s daratumumab, and Roche’s Pertuzumab rank 7 to 9 in the global best-selling oncology drug list, with sales exceeding 4 billion U.S. dollars. Respectively perform their duties in lung adenocarcinoma, multiple myeloma, and HER2+ breast cancer.